Enhancement of the Soluble Form of OX40 and OX40L Costimulatory Molecules but Reduction of the Membrane Form in Type 1 Diabetes (T1D)

Figure 1

Expression of mOX40 and its ligand mOX40L in the PBMC of T1D patients. (a) The expression level of mOX40 was detected by flow cytometry of CD3⁺, CD4⁺, and CD8⁺ T cells from T1D patients and HCs. (b) Percentages of CD3⁺OX40⁺, CD4⁺OX40⁺, and CD8⁺OX40⁺ cells in the PBMC samples of patients with T1D and HCs. (c) The expression level of mOX40L was detected by flow cytometry of monocyte cells from T1D patients and HCs. CD14 and CD19 were used as markers of monocytes and B cells. (d) A histogram representative of a set of CD14⁺OX40L⁺ and CD19⁺OX40L⁺ is shown in the right figure.

(a)

(b)

(c)

(d)